Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Latest news / News 2021 / ACCC helps to further protect Australians further protected against medicine shortages caused by COVID-19

ACCC helps to further protect Australians further protected against medicine shortages caused by COVID-19

December 12, 2021 By Admin

10 December 2021

Canberra, ACT

Canberra:

Medicine shortages from the COVID-19 pandemic will continue to be actively managed by Medicines Australia and Generic Biosimilar Medicines Association (GBMA) thanks to an authorisation confirmed by the ACCC today.

The authorisation extension will allow the Federal Government to work with Medicines Australia and GBMA to coordinate efforts and ensure the continued supply of essential medicines and devices.

Ms Elizabeth de Somer, CEO of Medicines Australia, said that the emergence of the Omicron variant demonstrates that disruption and shortage issues are far from over.

“All Australian businesses have felt the pressure on their supply chains, including challenges with freight delays. As the COVID pandemic continues it remains critical that we can continue to work together for Australian patients to have access to the medicines they need.”

“This ACCC authorisation allows us to continue to manage and minimise risks that could disrupt medicine supply to hospitals and patients,” said Ms de Somer.

Ms Marnie Peterson, CEO of the GBMA added that the ACCC authorisation will help deliver uninterrupted and timely access to the medicines Australians need.

“The COVID-19 pandemic has thrown disruption into everyone’s lives,” Ms Peterson said. “Behind the scenes, the Australian medicines industry has been working hard to protect Australians against global medicine supply chain shocks.”

Medicines Australia and GBMA both recently put into place respective Strategic Agreements with the Australian Government that will focus on timely access to innovative medicines, treatments and vaccines and further strengthen protection for patients from medicine shortages.

Medicines Australia and GBMA thanked the ACCC for their consideration and final authorisation. The authorisation has been granted for a period of 12 months, expiring on 30 September 2022.

–ENDS–

Media inquiries:

MEDICINES AUSTRALIA
Chrystianna Moran

0424 995 118
chrystianna.moran@medicinesaustralia.com.au

GBMA
Jannette Cotterell
Executive Counsel Australia
0419 204 059
jcotterell@executivecounsel.com.au


ABOUT MEDICINES AUSTRALIA

Medicines Australia leads the research-based medicines industry of Australia. Its members discover, develop and manufacture prescription pharmaceutical products, biotherapeutic products and vaccines that bring health, social and economic benefits to Australia. its members invest in Australian medical research and take local discoveries and developments to the world.

ABOUT GBMA

The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered high quality generic and biosimilar medicines, whilst providing affordable community health outcomes that benefit all Australians.

For more information, please contact the GBMA – admin@gbma.com.au or visit www.gbma.com.au

Filed Under: News 2021

Our Members

logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Health Minister, Greg Hunt MP and Shadow Health Minister, Mark Butler MP both applaud the role of the GBMA Strategic Agreement for the security of the supply of vital medicines

April 1, 2022

Friday March 1, 2022 Canberra, ACT In one of his last speeches in Parliament as the … More...

Health Minister, Greg Hunt MP and Shadow Minister, Mark Butler MP confirmed as VIP speakers at the GBMA Industry Budget Week luncheon

March 15, 2022

Embargoed until Tuesday March 15, 2022 Canberra, … More...

Australia’s peak body for affordable medicines welcomes a new board member

February 15, 2022

Embargoed until Tuesday February 15, 2022 Canberra, … More…

© 2022 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us